Overview

Buspirone Hydrochloride 30mg Tablets, Fasting

Status:
Completed

Trial end date:
2002-04-01

Target enrollment:

Participant gender:

Summary

This study will compare the relative bioavailability (rate and extent of absorption) of 30 mg Buspirone Hydrochloride Tablets by TEVA Pharmaceuticals Industries, Ltd. with that of 30 mg BUSPAR® Tablets by Bristol-Myers Squibb Company following a single oral dose (1 x 30 mg tablet) in healthy adult volunteers under fasting conditions.

Phase:

Phase 1

Details

Lead Sponsor:

Teva Pharmaceuticals USA

Treatments:

Buspirone